Research demonstrates finerenone improves diabetic nephropathy by suppressing SLC7A11-mediated ferroptosis in kidney cells, suggesting new therapeutic strategies.
Key Points
Finerenone, a non-steroidal mineralocorticoid receptor antagonist, shows promise in treating diabetic nephropathy.
The study highlights the role of ferroptosis as a key factor in diabetic tubulopathy and kidney damage.
SLC7A11-mediated ferroptosis was inhibited by finerenone, leading to reduced kidney inflammation and fibrosis.
These findings indicate that targeting ferroptosis could provide new approaches for managing kidney diseases in diabetes.